Fibrinogen–Albumin Ratio Index (FARI) as a Certain Prognostic Biomarker in Pretreated Patients with Immunotherapy

PURPOSE: Immunotherapy has become the standard treatment for advanced tumors so that many biomarkers play parts in predicting prognosis and clinical outcome. Use of FARI is increasing, but there are no studies on its use prior to immunotherapy. PATIENTS AND METHODS: A retrospective study prior to im...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Ziwei, Liang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163584/
https://www.ncbi.nlm.nih.gov/pubmed/34079370
http://dx.doi.org/10.2147/CMAR.S307272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163584/
https://www.ncbi.nlm.nih.gov/pubmed/34079370
http://dx.doi.org/10.2147/CMAR.S307272

Ejemplares similares